Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 357

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 357
---
 date they were available to be issued. F-109

Consulting Agreements with former Kineta employees Subsequent to the completion of the Kineta Merger, the Company entered into consulting agreements with sixformer Kineta employees which provides for the payment of a combination of cash and stock awards under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (the “2024 Equity Plan”). The amounts payable to such former Kineta employees are in satisfaction of separation payments that were assumed in connection with the Kineta Merger. Approximately 133,000shares of common stock were issued at $ 2.50per share under the 2024 Equity Plan. Additionally, the Company issued notes payable to fiveof the former employees totaling approximately $ 590,000in the aggregate at 10% interest payable monthly from August 15, 2025 to December 15, 2025. The sixemployees will also provide consulting services to the Company through September 30, 2025. Registration Statement on Form S-1 In connection with the Offering and the sale of shares of common stock and warrants to purchase common stock sold to the Purchasers pursuant to the Securities Purchase Agreement, the Company filed a registration statement on Form S-1,including the prospectus therein, relating to the resale of the common stock and the shares of common stock underlying the warrants from time to time purchased by the Purchasers.

<div align='center'>**F-110

Report of Independent Registered Public Accounting Firm**</div>

To the Board of Directors and Stockholders of Kineta, Inc.

### Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Kineta, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

#### Explanatory Paragraph – Going Concern
The accompanying consolidated financial statements have been prepared assuming that